The medical devices industry continues to be a hotbed of patent innovation. Activity is driven by increased need for homecare, preventative treatments, early diagnosis, reducing patient recovery times and improving outcomes, and growing importance of technologies such as machine learning, augmented reality, 5G and digitalization. In the last three years alone, there have been over 710,000 patents filed and granted in the medical devices industry, according to GlobalData’s report on Innovation in medical: intranasal drug delivery. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Innovation in medical: intranasal drug delivery

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

30+ innovations will shape the medical devices industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the medical devices industry using innovation intensity models built on over 155,000 patents, there are 30+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, ultrasonic nebulizers and intra-oral 3D imaging are disruptive technologies that are in the early stages of application and should be tracked closely. Intraocular pressure monitoring, automated diabetes management, and tissue repair implants are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas is CPR assistance devices, which is now well established in the industry.

Innovation S-curve for the medical devices industry

Intranasal drug delivery is a key innovation area in medical devices

Intranasal drug delivery is a non-invasive technique for administering medication via the nasal passage. It involves the introduction of medication in various forms, such as aerosols, gels, or dry powders, through the nasal cavity, facilitating rapid absorption into the bloodstream through the nasal mucosa. This approach is particularly beneficial for drugs requiring swift action.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 120+ companies, spanning technology vendors, established medical devices companies, and up-and-coming start-ups engaged in the development and application of intranasal drug delivery.

Key players in intranasal drug delivery – a disruptive innovation in the medical devices industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to custom intranasal drug delivery

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Syqe Medical 174 Unlock Company Profile
Grupo Ferrer Internacional 105 Unlock Company Profile
Insmed 98 Unlock Company Profile
Eli Lilly 98 Unlock Company Profile
Toko Pharmaceutical Industries 81 Unlock Company Profile
OptiNose 77 Unlock Company Profile
Opiant Pharmaceuticals 64 Unlock Company Profile
Aerami Therapeutics 54 Unlock Company Profile
Philip Morris International 54 Unlock Company Profile
Glenmark Pharmaceuticals 44 Unlock Company Profile
Sanofi 37 Unlock Company Profile
AbbVie 34 Unlock Company Profile
Portaero 32 Unlock Company Profile
Proto Pharma 31 Unlock Company Profile
Neurelis 28 Unlock Company Profile
Societal CDMO 28 Unlock Company Profile
Bryn Pharma 28 Unlock Company Profile
Altria Group 27 Unlock Company Profile
British American Tobacco 27 Unlock Company Profile
Impel Pharmaceuticals 26 Unlock Company Profile
InCarda Therapeutics 25 Unlock Company Profile
Emplicure 25 Unlock Company Profile
Shenzhen Hepalink Pharmaceutical Group 25 Unlock Company Profile
Ampio Pharmaceuticals 23 Unlock Company Profile
Kind Consumer 21 Unlock Company Profile
Cetylite Industries 21 Unlock Company Profile
Kyowa Kirin 19 Unlock Company Profile
Novopyxis 19 Unlock Company Profile
SipNose 18 Unlock Company Profile
Johnson & Johnson 17 Unlock Company Profile
Savara 15 Unlock Company Profile
Parion Sciences 15 Unlock Company Profile
Cardeas Pharma 14 Unlock Company Profile
Assertio 14 Unlock Company Profile
Hkl Medical 13 Unlock Company Profile
Nasaleze International 12 Unlock Company Profile
Enviroscent 12 Unlock Company Profile
Emergent BioSolutions 12 Unlock Company Profile
PARI Medical 11 Unlock Company Profile
St Renatus 11 Unlock Company Profile
Koninklijke Philips 11 Unlock Company Profile
Aerogen 10 Unlock Company Profile
Zambon 10 Unlock Company Profile
Otsuka 10 Unlock Company Profile
AYR 10 Unlock Company Profile
Evoke Pharma 10 Unlock Company Profile
Pfizer 10 Unlock Company Profile
Sensory Cloud 10 Unlock Company Profile
Luna Innovations 9 Unlock Company Profile
Galecto 9 Unlock Company Profile

Source: GlobalData Patent Analytics

Syqe Medical and Grupo Ferrer Internacional are two of the leading patent filers in intranasal drug delivery devices. Some other key patent filers include Insmed, Eli Lilly, and Toko Pharmaceutical Industries.

In terms of application diversity, Enviroscent leads the pack, while AYR and Koninklijke Philips stood in the second and third positions, respectively. By means of geographic reach, Insmed held the top position, followed by OptiNose and AbbVie.

Intranasal delivery of drugs directly to the central nervous system is being preferred as it circumvents the blood brain barrier. Intranasal drug delivery devices are expected to see increased usage in the coming years, due to their efficiency in facilitating quick and precise administration of drugs that lead to lower side effects and an increased patient adherence. Using advanced approaches such as nanomedicine and nanocarriers, intranasal drug delivery will represent an opportunity to treat currently incurable diseases.

To further understand the key themes and technologies disrupting the medical devices industry, access GlobalData’s latest thematic research report on Medical Devices.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.